Cargando…

Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer

BACKGROUND: Hepatic arterial infusion (HAI) of chemotherapy is an option for the treatment of patients with liver metastases from colorectal cancer (LMCRC). Though HAI with oxaliplatin (HAI-Ox) is generally used, intravenous (IV) 5-fluoro-uracil (5FU)-oxaliplatin-irinotecan HAI (HAI-Folfirinox) is f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Randrian, Violaine, Pernot, Simon, Sionneau, Baptiste, Smith, Denis, Lim, Annie, Touchefeu, Yann, Gallois, Claire, Turpin, Anthony, Javed, Sahir, Guimbaud, Rosine, Rivera, Pascale, Karoui, Mehdi, Auclin, Edouard, Taieb, Julien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243466/ https://www.ncbi.nlm.nih.gov/pubmed/35783637 http://dx.doi.org/10.3389/fmed.2022.830595

Ejemplares similares

Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'
por: Pernot, Simon, et al.
Publicado: (2016)

Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study
por: Alouani, E., et al.
Publicado: (2023)

Severe Generalized Weakness, Paralysis, and Aphasia following Administration of Irinotecan and Oxaliplatin during FOLFIRINOX Chemotherapy
por: Chandar, Manisha, et al.
Publicado: (2015)

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial
por: Auclin, Edouard, et al.
Publicado: (2019)

Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study
por: Javed, Sahir, et al.
Publicado: (2022)

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
por: Zhao, Yang, et al.
Publicado: (2019)

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
por: Portal, Alix, et al.
Publicado: (2015)

FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma
por: Vary, Antonin, et al.
Publicado: (2021)

Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies
por: Randrian, Violaine, et al.
Publicado: (2021)

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)
por: Lévi, Francis, et al.
Publicado: (2017)

Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
por: Williet, Nicolas, et al.
Publicado: (2019)

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study
por: Pernot, Simon, et al.
Publicado: (2020)

Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study
por: Zou, Lu, et al.
Publicado: (2021)

Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S‐1 as second‐line chemotherapy in metastatic pancreatic cancer
por: Ikezawa, Kenji, et al.
Publicado: (2021)

Hemolytic uremic syndrome following the infusion of oxaliplatin: case report
por: Dahabreh, Issa, et al.
Publicado: (2006)

Endoscopy to Diagnose and Prevent Digestive Cancers in Lynch Syndrome
por: Olivier, Raphael, et al.
Publicado: (2021)

Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
por: Williet, Nicolas, et al.
Publicado: (2021)

Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin
por: Zhao, Yang, et al.
Publicado: (2021)

Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?
por: Maman, Yossi, et al.
Publicado: (2023)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer
por: Evrard, Camille, et al.
Publicado: (2019)

A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer
por: Cheeseman, S L, et al.
Publicado: (2002)

Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
por: Yang, Feng, et al.
Publicado: (2019)

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study
por: Pernot, Simon, et al.
Publicado: (2018)

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial
por: Taïeb, Julien, et al.
Publicado: (2023)

Case Report: Two Cases of Metastatic Pancreatoblastoma in Adults: Efficacy of Folfirinox and Implication of the Wnt/β-Catenin Pathway in Genomic Analysis
por: Raoul, Jean-Luc, et al.
Publicado: (2021)

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study
por: Vienot, Angélique, et al.
Publicado: (2020)

Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers
por: Evrard, Camille, et al.
Publicado: (2022)

Pancreatic cancer and FOLFIRINOX: a new era and new questions
por: Marsh, Robert De W, et al.
Publicado: (2015)

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy
por: Guion-Dusserre, Jean-Florian, et al.
Publicado: (2016)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
por: Sakr, Amr, et al.
Publicado: (2020)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Cancer of Unknown Primary With Presumptive Pancreatic Cancer Treated With FOLFIRINOX
por: Inoue, Naonori, et al.
Publicado: (2021)

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis
por: Zhang, Beilei, et al.
Publicado: (2021)

Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307)
por: Nuemi, Gillles, et al.
Publicado: (2015)

A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases
por: Feng, Ai-Wei, et al.
Publicado: (2022)

Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
por: Bui, Quang Loc, et al.
Publicado: (2022)

Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176
por: Auclin, Edouard, et al.
Publicado: (2021)

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer
por: Oar, Andrew, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9jkeg5uc6263k99no1qi416put